Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
ConditionStomach Neoplasm
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorWest China Hospital
About this trial
The median survival time of first-line chemotherapy for advanced gastric cancer is about one year, and the treatment is still facing the bottleneck. This is a one-arm, open and prospective phase II clinical study. Recruit patients who have been diagnosed with advanced or metastatic adenocarcinoma of the stomach and gastroesophageal junction and have not received systematic treatment.
Eligibility criteria
Qualifiers
Histological or cytological diagnosis confirmed adenocarcinoma of stomach and gastroesophageal junction (including signet ring cell carcinoma, mucinous adenocarcinoma, hepatoid adenocarcinoma)
Imaging and surgical evaluation of unresectable recurrent or metastatic patients
The expected survival time was more than 3 months
The age is between 18 and 70 years old, both male and female
Disqualifiers
Female subjects of childbearing age were required to conduct a serum pregnancy test within 3 days before the start of the study, and the results were negative, and they were willing to use a medically recognized high-efficiency contraceptive method (such as intrauterine device, contraceptive or condom) during the study period and within 3 months after the last administration of the study drug;For male subjects whose partners are women of childbearing age, they should be sterilized by surgery or agree to use effective contraceptive methods during the study and within 3 months after the last study administration
With my consent and signed the letter of understanding, I am willing and able to follow the planned visit, research treatment, laboratory examination and other test procedures
HER2 + (or HER2 +) is known to be positive
Gastric cancer known as squamous cell carcinoma, undifferentiated or other tissue types, or adenocarcinoma mixed with other tissue types
Trial design
Treatments tested in this trial
- Capeox regimen combined with Sintilimab and Bevacizumab
Treatment groups
57 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov